Concurrent immunotherapy improves progression-free survival but increases toxicity in unresectable stage III NSCLC. Qin Y, Mo Y, Li P, Liang X, et al. Lung Cancer 2025;203:108544.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Qin Y, Mo Y, Li P, Liang X, et al. Concurrent immunotherapy improves progression-free survival but increases toxicity in unresectable stage III NSCLC. Lung Cancer 2025;203:108544.
PMID: 40253944